A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.
Inclusion Criteria:
Exclusion Criteria:
Vienna, 1090, Austria
Lübeck, 23538, Germany
Debrecem, 4032, Hungary
Udine, Veneto 33100, Italy
Krakow, 31-501, Poland
Bratislava, 851 07, Slovakia
L'Hospitalet de Llobregat, Barcelona 8907, Spain
Gloucestershire, GL1 3NN, United Kingdom
Liverpool, L7 8XP, United Kingdom